CircuThe insulin-like growth factor-1 and expression of its binding protein-3 in chronic hepatitis C and hepatocellular carcinoma

Oncology Reports

Volumn 30, Issue 3, 2013, Pages 1337-1345

  Adamek, Agnieszka ^a   Kasprzak, Aldona ^b   Mikos, Hanna ^c   Przybyszewska, Wieslawa ^b   Seraszek Jaros, Agnieszka ^b   Czajka, Arkadiusz ^a   Sterzynska, Karolina ^b   Mozer Lisewska, Iwona ^a  

^a Departments of Infectious Diseases   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c Departments of Pediatric Endocrinology and Diabetes   (Poland)

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; Insulin like growth factor binding protein 3; Insulin like growth factor 1; Insulin like growth factor 1 insulin like growth factor binding protein 3 ratio

Indexed keywords

ALPHA FETOPROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; IGFBP3 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER LEVEL; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION; ADOLESCENT; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; LIVER; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; IMMUNOENZYME TECHNIQUES; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84880574812     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2546     Document Type: Article

References (52)

1. Fattovich G, Stroffolini T, Zagni I and Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127: S35-S50, 2004.
2. Rehermann B and Nascimbeni M: Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5: 215-229, 2005.
3. Colombo M: Hepatitis C virus and hepatocellular carcinoma. Semin Liver Dis 19: 263-269, 1999.
4. Anzola M: Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat 11: 383-393, 2004.
5. Kasprzak A and Adamek A: Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Hepatol Res 38: 1-26, 2008.
6. Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G and Groyer A: An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocellular cells against drug-induced apoptosis. Biochem Pharmacol 86: 1003-1015, 2004.
7. Kasprzak A and Adamek A: The insulin-like growth factor (IGF) signaling axis and hepatitis C virus-associated carcinogenesis (Review). Int J Oncol 41: 1919-1931, 2012.
8. Daughday WH and Rotweien P: Insulin-like growth factors I and II: peptide, messenger ribonucleic acid, and gene structures, serum and tissue concentrations. Endocr Rev 10: 68-91, 1989.
9. Zarilli R, Bruni CB and Riccio A: Multiple levels of control of insulin-like growth factor gene expression. Mol Cell Endocrinol 101: R1-R14, 1994.
10. Juul A, Bang P, Hertel NT, et al: Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 78: 744-752, 1994.
11. Brabant G and Wallaschofski H: Normal levels of serum IGF-I: determinants and validity of current reference ranges. Pituitary 10: 129-133, 2007.
12. Kostecka Y and Blahovec J: Insulin-like growth factor binding proteins and their functions (minireview). Endocr Regul 33: 90-94, 1999.
13. Le Roith D, Bondy C, Yakar S, Liu JL and Butler A: The somatomedin hypothesis: 2001. Endocr Rev 22: 53-74, 2001.
14. Elmlinger MW, Kühnel W, Weber MM and Ranke MB: Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 42: 654-664, 2004.
15. Yu H, Mistry J, Nicar MJ, Khosravi MJ, Diamandis A, van Doorn J and Juul A: Insulin-like growth factors (IGF-I, free IGF-I, and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation. J Clin Lab Anal 13: 166-172, 1999.
16. Juul A, Dalgaard P, Blum WF, et al: Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 80: 2534-2542, 1995.
17. Mattsson A, Svensson D, Schuett B, Osterziel KJ and Ranke MB: Multidimensional reference region for IGF-I, IGFBP-2 and IGFBP-3 concentrations in serum healthy adults. Growth Horm IGF Res 18: 506-516, 2008.
18. Raslan HM, Elhosary Y, Ezzat WM, Rasheed EA and Rasheed MA: The potential role of insulin-like growth factor 1, insulin-like growth factor binding protein 3 and bone mineral density in patients with chronic hepatitis C virus in Cairo, Egypt. Trans R Soc Trop Med Hyg 104: 429-432, 2010.
19. Blum WF, Albertsson-Wikland K, Rosberg S and Ranke MB: Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab 76: 1610-1616, 1993.
20. Wu JC, Daughaday WH, Lee SD, et al: Radioimmunoassay of serum IGF-I and IGF-II in patients with chronic liver diseases and hepatocellular carcinoma with or without hypoglycemia. J Lab Clin Med 112: 589-594, 1988.
21. Kratzsch J, Blum WF, Schenker E and Keller E: Regulation of growth hormone (GH), insulin-like growth factor (IGF) I, IGF binding proteins -1, -2, -3 and GH binding protein during progression of liver cirrhosis. Exp Clin Endocrinol Diabetes 103: 285-291, 1995.
22. Völzke H, Nauck M, Rettig R, Dörr M, Higham C, Brabant G and Wallaschofski H: Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample. Eur J Endocrinol 161: 705-713, 2009.
23. Rehem RN and El-Shikh WM: Serum IGF-1, IGF-2 and IGFBP-3 as a parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma. Hepatogastroenterology 58: 949-954, 2011.
24. Vyzantiadis T, Theodoridou S, Giouleme O, Harsoulis P, Evgenidis N and Vyzantiadis A: Serum concentrations of insulin-like growth factor-I (IGF-I) in patients with liver cirrhosis. Hepatogastroenterology 50: 814-816, 2003.
25. Lorenzo-Zúñiga V, Bartolí R, Masnou H, Montoliu S, Morillas RM and Planas R: Serum concentration of insulin-like growth factor-I (igf-I) as a marker of liver fibrosis in patients with chronic hepatitis C. Dig Dis Sci 52: 3245-3250, 2007.
26. Nikolić JA, Todorović V, Bozić M, et al: Serum insulin-like growth factor (IGF)-II is more closely associated with liver disfunction than is IGF-I in patients with cirrhosis. Clin Chim Acta 294: 169-177, 2000.
27. Stuver SO, Kuper H, Tzonou A, Lagiou P, Spanos E, Hsieh CC, Mantzoros C and Trichopoulos D: Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men. Int J Cancer 87: 118-121, 2000.
28. Wu YL, Ye J, Zhang S, Zhong J and Xi RP: Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis. World J Gastroenterol 10: 2740-2743, 2004.
29. Mazziotti G, Sorvillo F, Morisco F, et al: Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer 95: 2539-2545, 2002.
30. Okan A, Cömlekçi A, Akpinar H, Okan I, Yeşil S, Tankurt E and Simşek I: Serum concentration of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in patients with chronic hepatitis. Scand J Gastroenterol 35: 1212-1215, 2000.
31. Raslan H, Ezzat W, Ahmed M and Rasheed E: Insulin growth-factor-1 and insulin-like growth factor binding protein-3 in Egyptian patients with chronic hepatitis C. Arch Med Sci 3: 46-51, 2007.
32. Su WW, Lee KT, Yeh YT, Soon MS, Wang CL, Yu ML and Wang SN: Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: one cross-sectional correlation study. J Clin Lab Anal 24: 195-200, 2010.
33. Morali G, Shitrit AB, Eran M, Freier S, Reinus C and Braverman D: Hepatic production of insulin-like growth factors in normal and diseased liver. Hepatogastroenterology 52: 1511-1515, 2005.
34. Stefano JT, Correa-Giannella ML, Ribeiro CMF, Alves VAF, Massarollo PCB, Machado MCC and Giannella-Neto D: Increased hepatic expression of insulin-like growth factor-I receptor in chronic hepatitis C. World J Gastroenterol 28: 3821-3828, 2006.
35. Huynh H, Chow PKH, Ooi LLP and Soo KC: A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ 13: 115-122, 2002.
36. Clemmons DR: Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 8: 45-62, 1997.
37. Kasprzak A, Adamek A, Przybyszewska W, et al: Expression of IGF-1 and viral proteins (C, NS3, NS5A) in the livers of patients with chronic HCV infection. Adv Clin Exp Med 20: 263-273, 2011.
38. Bedossa P and Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24: 289-293, 1996.
39. Kasprzak A, Adamek A, Biczysko W, et al: Intracellular expression of the proliferative marker Ki-67 and viral proteins (NS3, NS5A and C) in chronic, long lasting hepatitis C virus (HCV) infection. Folia Histochem Cytobiol 45: 357-366, 2007.
40. Hsu SM, Raine L and Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577-580, 1981.
41. Kaczmarek E and Strzelczyk R: From two to three-dimensional visualisation of structures in light and confocal microscopy - applications for biomedical studies. In: Current Issues on Multidisciplinary Microscopy Research and Education. Mendez-Vilas A, Labajos-Broncano L (eds). FORMATEX microscopy book series no. II Formatex Research Centre, Badajoz, pp289-295, 2005.
42. Mahdy KA, Ahmed HH, Mannaa F and Abdel-Shaheed A: Clinical benefits of biochemical markers of bone turnover in Egyptian children with chronic liver diseases. World J Gastroenterol 13: 785-790, 2007.
43. Aimaretti G, Boschetti M, Corneli G, et al: Normal age-dependent values of serum insulin growth factor-I: results from a healthy Italian population. J Endocrinol Invest 31: 445-449, 2008.
44. Andreassen M, Nielsen K, Raymond I, Kristensen Lø and Faber J: Characteristics and reference ranges of insulin-like growth factor-I measured with a commercially available immunoassay in 724 healthy adult Caucasians. Scand J Clin Lab Invest 69: 880-885, 2009.
45. Rosario PW: Normal values of serum IGF-1 in adults: results from a Brazilian population. Arq Bras Endocrinol Metabol 54: 477-481, 2010.
46. Holmes MD, Pollak MN and Hankinson SE: Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 11: 862-867, 2002.
47. Colakoǧlu O, Taşkiran B, Colakoǧlu G, Kizildaǧ S, Ari Ozkan F and Unsal B: Serum insulin like growth factor-1 (IGF-1) and insulin growth factor binding protein-3 (IGFBP-3) levels in liver cirrhosis. Turk J Gastroenterol 18: 245-249, 2007.
48. Plöckinger U, Krüger D, Bergk A, Weich V, Wiedenmann B and Berg T: Hepatitis-C patients have reduced growth hormone (GH) secretion which improves during long-term therapy with pegylated interferon-alpha. Am J Gastroenterol 102: 2724-2731, 2007.
49. Ichikawa T, Nakao K, Hamasaki K, et al: Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development on non-alcoholic fatty liver disease. Hepatol Int 1: 287-294, 2007.
50. Arany E, Afford S, Strain AJ, Winwood PJ, Arthur MJ and Hill DJ: Differential cellular synthesis of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 within human liver. J Clin Endocrinol Metab 79: 1871-1876, 1994.
51. Ross RJM, Chew SL, D'Souza Li L, et al: Expression of IGF-I and IGF-binding protein genes in cirrhotic liver. J Endocrinol 149: 209-216, 1996.
52. Mattera D, Capuano G, Colao A, Pivonello R, Manguso F, Puzziello A and D'Agostino L: Increased IGF-I:IGFBP-3 ratio in patients with hepatocellular carcinoma. Clin Endocrinol (Oxf) 59: 699-706, 2003.